
|Videos|July 1, 2020
Expanding Options for Relapsed/Refractory Gastrointestinal Stromal Tumors
Author(s)Targeted Oncology
Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
4
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
5


































